93 related articles for article (PubMed ID: 9072220)
1. [The morphological aspects of a study of the efficacy of chemotherapy in ovarian cancer].
Iakymova TP; Pavlova TD; Kartashov SM; Iakymov DIu
Lik Sprava; 1996; (7-9):103-6. PubMed ID: 9072220
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.
Grivas A; Lianos E; Internos I; Papaxoinis G; Tselepatiotis E; Ziras N; Athanasiou AE
J BUON; 2010; 15(4):647-51. PubMed ID: 21229624
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin and cyclophosphamide, alternated with bleomycin and mitomycin C as a second-line regimen in advanced ovarian carcinoma resistant to cisplatin-based chemotherapy.
Benedetti Panici P; Scambia G; Greggi S; Salerno G; Cento R; Mancuso S
Oncology; 1990; 47(4):296-8. PubMed ID: 1694980
[TBL] [Abstract][Full Text] [Related]
4. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
[TBL] [Abstract][Full Text] [Related]
5. Re: Mucinous ovarian cancer.
Omura GA
Gynecol Oncol; 2005 Dec; 99(3):789; author reply 789-90. PubMed ID: 16125757
[No Abstract] [Full Text] [Related]
6. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO III and IV) as measured by surgical end-staging (second-look surgery)--the mount sinai experience.
Cohen CJ; Bruckner HW; Goldberg JD; Holland JF
Clin Obstet Gynaecol; 1983 Aug; 10(2):307-24. PubMed ID: 6413114
[No Abstract] [Full Text] [Related]
7. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0).
Sakuragi N; Yamada H; Oikawa M; Okuyama K; Fujino T; Sagawa T; Fujimoto S
Gynecol Oncol; 2000 Nov; 79(2):251-5. PubMed ID: 11063653
[TBL] [Abstract][Full Text] [Related]
10. [Synchronous double cancers in the ovary and kidney--a case report].
Myoga H; Tamaki M; Shinko Y; Ohta S; Shigemasa K; Nogawa T; Katsube Y; Fujiwara A
Gan No Rinsho; 1988 Nov; 34(14):2007-14. PubMed ID: 2849689
[TBL] [Abstract][Full Text] [Related]
11. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P
Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic factors of common epithelial ovarian cancer treated by surgery and cisplatin based combination chemotherapy].
Sasaki H; Ochiai K; Terashima Y; Mochizuki S; Soda T; Nishimura H; Yakushiji M; Hirabayashi M
Gan No Rinsho; 1989 Oct; 35(13):1615-20. PubMed ID: 2585733
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
14. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy.
Bamias A; Psaltopoulou T; Sotiropoulou M; Haidopoulos D; Lianos E; Bournakis E; Papadimitriou C; Rodolakis A; Vlahos G; Dimopoulos MA
Cancer; 2010 Mar; 116(6):1462-8. PubMed ID: 20108307
[TBL] [Abstract][Full Text] [Related]
15. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia.
Lancet; 1987 Aug; 2(8555):353-9. PubMed ID: 2886821
[TBL] [Abstract][Full Text] [Related]
16. [Progress in the chemotherapy of ovarian cancer].
Honetz N
Wien Med Wochenschr; 1982 Jul; 132(13-14):319-24. PubMed ID: 6291259
[No Abstract] [Full Text] [Related]
17. Cis-platin-Mecy as salvage chemotherapy in recurrent advanced ovarian carcinoma.
Belli M; Colantuoni G; Di Iorio B
G Ital Oncol; 1989; 9(1):31-3. PubMed ID: 2785083
[TBL] [Abstract][Full Text] [Related]
18. Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma.
Shimizu Y
Gan To Kagaku Ryoho; 1997 May; 24 Suppl 1():61-9. PubMed ID: 9210889
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
Anand A; Anand A; Anand N
Cancer; 1996 May; 77(9):1959-60. PubMed ID: 8646700
[No Abstract] [Full Text] [Related]
20. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
